LiGHT System
Proton Beam Therapy


AVOplc, - Advanced Oncotherapy, a UK headquartered specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, is bringing the World’s most advanced cancer treatment to the emerging markets .
AVO’s LIGHT technology is the result of 25 years of research work at CERN and ADAM. AVO’s focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient's healthy tissues.
​
-
the head office in London, UK
-
the R&D facility ADAM S.A. (Applications of Detectors and Accelerators to Medicine), in Geneva, Switzerland
-
the US operations in Syracuse, NY
Overview of the LiGHT System
The presentation of the AVO's LIGHT Proton Therapy Solution is part of our Development roadmap and is subject to conformity assessment(s) by AVO's Notified Body as well as 510(k) clearance by the USA-FDA.


To offer increased precision
​
The linear design of LIGHT allows for (i) an active longitudinal modulation along the proton beam axis and (ii) the variation of the proton beam by electronic means during cancer treatment. The modular feature of LIGHT offers hospitals and treatment centres the flexibility to customise cancer treatment plans based on a wide range of energies. Potentially, this could provide an alternative to passive modulation, that degrades the beam along its path, causing it to lose integrity. Moreover, a dynamic transversal modulation allows a precise 3D treatment of the tumours via the 'spot scanning' technique.
​
​
​
​
To strive for user-friendliness
​
Linear proton beam accelerators are similar in use to the conventional x-ray linear accelerators currently used for cancer treatment. This similarity offers doctors and medical technicians a familiar approach in LIGHT. Associated with straightforward design principles, LIGHT is designed to allow for accessible maintenance during the short shut-down periods of the system.
The presentation of the AVO's LIGHT Proton Therapy Solution is part of our Development roadmap and is subject to conformity assessment(s) by AVO's Notified Body as well as 510(k) clearance by the USA-FDA.